Patents by Inventor Dehua Pei

Dehua Pei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11987647
    Abstract: Disclosed are cell penetrating peptides and compositions comprising such peptides that can be used to deliver agents to various cell types.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 21, 2024
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Patent number: 11987821
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: May 21, 2024
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Natarajan Sethuraman, Jason Ruth, Louis A. Tartaglia, Dehua Pei, Ziqing Qian
  • Publication number: 20240158445
    Abstract: Provided herein are novel cyclic cell penetrating peptides comprising at least two arginines and at least three hydrophobic amino acids. The disclosure also provides methods of using the cyclic cell penetrating peptides to transport cargo into cells and to treat diseases.
    Type: Application
    Filed: February 22, 2022
    Publication date: May 16, 2024
    Inventors: Dehua Pei, Marina Buyanova
  • Publication number: 20240150404
    Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF? TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 9, 2024
    Inventor: Dehua PEI
  • Publication number: 20240101509
    Abstract: Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.
    Type: Application
    Filed: October 31, 2023
    Publication date: March 28, 2024
    Inventors: Dehua PEI, George APPIAH KUBI, Ziqing QIAN
  • Publication number: 20240033318
    Abstract: Described are peptides and peptide conjugates comprising CN binding motifs (CNBM) which inhibit the CN-NFAT interaction. In some embodiments, the peptides comprise: (i) CNBM; (ii) a hydrophobic, non-peptidic moiety (RH) which interacts with the hydrophobic pocket on a CN protein; (iii) a sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-, wherein each of AAU2, AAU3, AAU4, AAU5, and AAU6, is, independently, optional, and each of AAU1, AAU2, AAU3, AAU4, AAU5, and AAU6 when present is independently an amino acid as defined herein; or (iv) combinations thereof. In some embodiments, RH is conjugated to the N- or C-terminus of the CNBM. In some embodiments, the sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6- is conjugated to the N- or C terminus of the CNBM. In some embodiments, the peptides comprise: CNBM and RH. In some embodiments. In some embodiments, the peptides comprise: CNBM and AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-. In some embodiments, the peptides of the disclosure CNBM and RH.
    Type: Application
    Filed: February 1, 2023
    Publication date: February 1, 2024
    Inventors: Dehua PEI, John W. CHRISTMAN, Manjula KARPURAPU, Patrick G. DOUGHERTY
  • Patent number: 11878046
    Abstract: Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformationally constrained bicyclic structure through the formation of a pair of disulfide bonds. The resulting bicyclic peptide has greatly enhanced proteolytic stability as well as cell-permeability. Once inside the cell, the disulfide bonds are reduced to produce a linear, biologically active peptide. This strategy was applied to generate a cell-permeable bicyclic peptidyl inhibitor against the NEMO-IKK interaction.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: January 23, 2024
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian
  • Patent number: 11859019
    Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF? TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: January 2, 2024
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Patent number: 11814341
    Abstract: Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: November 14, 2023
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Dehua Pei, George Appiah Kubi, Ziqing Qian
  • Patent number: 11793884
    Abstract: Described herein, in various embodiments, are peptides comprising: (i) a cyclic cell-penetrating peptide sequence (cCPP) and (ii) a CAL-PDZ binding sequence, which is conjugated, directly or indirectly, to an N-terminus of an amino acid in the cCPP, to a C-terminus of an amino acid on the cCPP, or on a side chain of an amino acid in the cCPP. In other embodiments, the peptides further comprise a physiologically cleavable group, wherein after entering the cell, the physiologically cleavable group is reduced, thereby providing a linear peptide. Without being bound by theory, the inventors discovered that the amino acid sequence in the cCPP, which facilities cytosolic delivery of the CAL-PDZ binding sequence also, surprisingly and unexpectedly, synergistically improves binding of CAL-PDZ binding sequence to the CAL-PDZ binding domain. Additionally, the cCPP sequence may also improve selectivity of the CAL-PDZ binding sequence for the CAL-PDZ domain relative to other PDZ binding domains.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 24, 2023
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Patrick G. Dougherty
  • Publication number: 20230322859
    Abstract: The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the I?B kinase ?/? (IKK?/?)-binding domain of NF-?B essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKK? interaction, thereby selectively inhibiting canonical NF-?B signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 12, 2023
    Inventor: Dehua PEI
  • Publication number: 20230212235
    Abstract: The present disclosure provides modified looped proteins comprising at least one looped region, wherein the at least one looped region comprises a cell penetrating peptide (CPP). In some embodiments, the present disclosure provides polynucleotides encoding the modified looped proteins and methods for their production.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 6, 2023
    Inventor: Dehua PEI
  • Patent number: 11673919
    Abstract: The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the I?B kinase ?/? (IKK?/?)-binding domain of NF-?B essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKK? interaction, thereby selectively inhibiting canonical NF-?B signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: June 13, 2023
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Publication number: 20230106131
    Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptide comprising a peptide and at least one staple which holds the peptide in an ?-helical conformation, and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the stapled peptide. The present disclosure demonstrates that cCPPs can be used to confer consistent cell-permeability to stapled peptides.
    Type: Application
    Filed: August 5, 2022
    Publication date: April 6, 2023
    Inventor: Dehua PEI
  • Patent number: 11576946
    Abstract: Described are peptides and peptide conjugates comprising CN binding motifs (CNBM) which inhibit the CN-NFAT interaction. In some embodiments, the peptides comprise: (i) CNBM; (ii) a hydrophobic, non-peptidic moiety (RH) which interacts with the hydrophobic pocket on a CN protein; (iii) a sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-, wherein each of AAU2, AAU3, AAU4, AAU5, and AAU6, is, independently, optional, and each of AAU1, AAU2, AAU3, AAU4, AAU5, and AAU6 when present is independently an amino acid as defined herein; or (iv) combinations thereof. In some embodiments, RH is conjugated to the N- or C-terminus of the CNBM. In some embodiments, the sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6- is conjugated to the N- or C terminus of the CNBM. In some embodiments, the peptides comprise: CNBM and RH. In some embodiments. In some embodiments, the peptides comprise: CNBM and AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-. In some embodiments, the peptides of the disclosure CNBM and RH.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: February 14, 2023
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, John W. Christman, Manjula Karpurapu, Patrick G. Dougherty
  • Patent number: 11510991
    Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptide comprising a peptide and at least one staple which holds the peptide in an ?-helical conformation, and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the stapled peptide. The present disclosure demonstrates that cCPPs can be used to confer consistent cell-permeability to stapled peptides.
    Type: Grant
    Filed: October 28, 2018
    Date of Patent: November 29, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Patent number: 11471535
    Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptide comprising a peptide and at least one staple which holds the peptide in an ?-helical conformation, and a cyclic cell-penetrating peptide (cCPP) conjugated, directly or indirectly, to the stapled peptide. The present disclosure demonstrates that cCPPs can be used to confer consistent cell-permeability to stapled peptides.
    Type: Grant
    Filed: October 28, 2018
    Date of Patent: October 18, 2022
    Assignee: Ohio State Innovation Foundation
    Inventor: Dehua Pei
  • Publication number: 20220315631
    Abstract: The present disclosure provides novel polypeptide conjugates. The polypeptide conjugates disclosed herein comprise a stapled peptidyl beta-catenin ligand and at least one staple which holds the peptidyl ligand in an ?-helical confirmation, and a cell-penetrating peptide (CPP) conjugated, directly or indirectly, to the stapled peptide.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 6, 2022
    Inventor: Dehua PEI
  • Publication number: 20220306693
    Abstract: Disclosed herein are peptides having activity as cell penetrating peptides. In some embodiments, the peptides can comprise a cell penetrating peptide moiety and beta-haripin turn creating moiety. In other embodiments, the peptides also comprise a cargo moiety.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 29, 2022
    Inventors: Dehua PEI, Ziqing QIAN
  • Publication number: 20220281920
    Abstract: The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the I?B kinase ?/? (IKK?/?)-binding domain of NF-?B essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKK? interaction, thereby selectively inhibiting canonical NF-?B signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Inventor: Dehua PEI